Results for 79 patients with neuroblastoma detected through mass screening at 6 months of age in a single institute

Pediatrics International

Volumn 48, Issue 6, 2006, Pages 531-535

  Nishio, Nobuhiro ^a   Mimaya, Jun Ichi ^a   Nara, Taemi ^a   Takashima, Yoshifumi ^a   Horikoshi, Yasuo ^a   Urushihara, Naoto ^a   Hasegawa, Shiro ^a   Aoki, Katsuhiko ^a   Hamasaki, Minoru ^a  

^a SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

Author keywords

Complication; Mass screening; Neuroblastoma; Observation

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; HOMOVANILLIC ACID; PIRARUBICIN; VANILMANDELIC ACID; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SCREENING; HETEROZYGOSITY LOSS; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MASS SCREENING; NEUROBLASTOMA; ONCOGENE MYC; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HOMOVANILLIC ACID; HUMANS; INFANT; JAPAN; MASS SCREENING; MEDIASTINAL NEOPLASMS; NEOPLASM REGRESSION, SPONTANEOUS; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VANILMANDELIC ACID;

EID: 33751382750     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2006.02284.x     Document Type: Article

References (23)

1. Sawada T, Kidowaki T, Sakamoto I et al. Neuroblastoma: mass screening for early detection and its prognosis. Cancer 1984; 53: 2731-5.
2. Kaneko Y, Kanda N, Maseki N et al. Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: a chromosome and N-myc amplifi cation study. J. Clin. Oncol. 1990; 8: 2005-13.
3. Yamamoto K, Hanada R, Kikuchi A et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J. Clin. Oncol. 1998; 16: 1265-9.
4. Nishihira H, Toyoda Y, Tanaka Y et al. Natural course of neuroblastoma detected by mass screening: a 5-year prospective study at a single institute. J. Clin. Oncol. 2000; 18: 3012-17.
5. Okazaki T, Kohno S, Hasegawa S et al. Neuroblastoma detected by mass screening: the Tumor board's role in its treatment. Pediatr. Surg. Int. 2004; 20: 27-32.
6. Terashima K, Horikoshi Y, Mimaya J et al. Prospective natural-history-study of patients with neuroblastoma detected by mass screening after short course of chemotherapy. J. Clin. Exp. Med. 2002; 200: 983-4 (in Japanese).
7. Sawada T, Kidowaki T, Sakamoto I et al. Neuroblastoma. Mass screening for early detection and its prognosis. Cancer 1984; 53: 2731-5.
8. Nishi M, Miyake H, Takeda T et al. Effects of the mass screening of neuroblastoma in Sapporo City. Cancer 1987; 60: 433-6.
9. Takeda T, Hatae Y, Nakadate H et al. Japanese experience of screening. Med. Pediatr. Oncol. 1989; 17: 368-72.
10. Sawada T, Matsumura T, Kawakatsu H et al. Long-term effects of mass screening for neuroblastoma in infancy. Am. J. Pediatr. Hematol. Oncol. 1991; 13: 3-7.
11. Bessho F, Hashizume K, Nakajo T, Kamoshita S. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J. Pediatr. 1991; 119: 237-41.
12. Woods WG, Tuchman M, Robison LL et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996; 348: 1682-7.
13. Woods WG, Tuchman M, Robison LL et al. Screening for neuroblastoma is ineffective in reducing the incidence of unfavorable advanced stage disease in older children. Eur. J. Cancer 1997; 33: 2106-12.
14. Bergeron C, Tafese T, Kerbl R et al. European experience with screening for neuroblastoma before the age of 12 months. Med. Pediatr. Oncol. 1998; 31: 442-9.
15. Schilling FH, Spix C, Berthold FE et al. German neuroblastoma mass screening study at 12 months of age: statistical aspects and preliminary results. Med. Pediatr. Oncol. 1998; 31: 435-41.
16. Parker L, Powell J. Screening for neuroblastoma in infants younger than 1 year of age: review of the first 30 years. Med. Pediatr. Oncol. 1998; 31: 455-69.
17. Erttman R, Tafese T, Berthold F et al. 10 year's neuroblastoma screening in Europe: preliminary results of a clinical and biological review from the Study Group for Evaluation of Neuroblastoma Screening in Europe (SENSE). Eur. J. Cancer 1998; 34: 1391-7.
18. Woods WG, Tuchman M, Bernstein M et al. Screening infants for neuroblastoma does not reduce the incidence of poor prognosis disease. Med. Pediatr. Oncol. 1998; 31: 450-54.
19. Suita S, Sawada T, Kaneko M et al. The report from the committee of neuroblastoma of Japanese Society of Pediatric Oncology - the present conditions and problems of mass screening at six month of age - . Jpn. J. Pediatr. Oncol. 1999; 36: 107-17 (in Japanese).
20. Ajiki W, Tsukuma H, Oshima A, Kawa K. Effects of mass screening for neuroblastoma on incidence and mortality, and survival rates in Osaka, Japan. Cancer Causes Control 1998; 9: 631-6.
21. Hisashige A. Epidemiological evaluation of mass screening - the influence to occurrence rate and mortality rate of neuroblastoma - . Jpn. J. Pediatr. Oncol. 2000; 37: 341.
22. Schilling FH, Spix C, Berthold F et al. Neuroblastoma screening at one year of age. N. Engl. J. Med. 2002; 346: 1047-53.
23. Woods WG, Gao RN, Schuster JJ et al. Screening of infants and mortality due to neuroblastoma. N. Engl. J. Med. 2002; 346: 1041-6.